With years of experience in the field of Antibody engineering, Creative Biolabs released Native™ Shark Antibody Discovery Service for shark antibody production.
Creative Biolabs is glad to develop monoclonal shark antibody production service for antibody researchers from all over the world. With their shark immunization and phage display technology, the novel monoclonal shark antibodies can be obtained with high specificity and affinity.
As we know, sharks have been in existence for over 500 million years. From an evolutionary perspective of vies, they are among the oldest animals with a “modern” immune system not unlike that of humans. Shark blood contains large quantities of urea that makes their antibodies much more robust than that of other vertebrates. While urea protects sharks from dehydration, it can also destabilize sensitive protein molecules such as antibodies.
Compared to the various immunoglobulin isotypes produced by other species, sharks, on the other hand, mainly produce IgM, IgW and IgNAR (immunoglobulin new antigen receptor).
IgNAR is a heavy chain homodimer, which consists of five constant domains and one variable region (VNAR) for each heavy chain. Meanwhile, relevant researches also indicated that IgNAR has several disulfide bonds in unusual positions, an extended loop formed in CDR3, a deletion in the FR2-CDR2 region and smaller size than standard antibodies. These differences result in remarkable stability and penetrability of IgNAR and enable the function under extreme conditions.
Meanwhile, it is much easier for VNAR to access to clefts, grooves or buried epitopes from the target surface that cannot be reached by larger antibody fragments, and it can also penetrate into dense tissues, such as tumors. In this way, VNAR is also considered a wonderful source for the development of single domain antibodies, which can contribute to various researches and pharmaceutical applications.
With years of antibody development and research experience, scientists of Creative Biolabs have developed the Native™ Antibody Discovery Platform to generate monoclonal antibody with native and in vivo characteristics. This platform takes advantage of the antigen-specific B lymphocytes cytometry technology, and can generate large scale of candidate shark antibodies in one step.
“Our scientists take pride in having earned great reputation from our global clients by satisfactorily completed thousands of relevant projects in the past decade. We are therefore confident in offering the best and most suitable service for our customer to meet each of their specific demands”, said Dr. Monika, scientific officer of Creative Biolabs.
About Creative Biolabs
Creative Biolabs is specialized in providing custom biotechnology and pharmaceutical services that cover the full scope of biotechnology needs of early antibody drug discovery and development.